澳股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

CLARITY PHARMACEUTICALS LTD

2.900

+0.1706.23%

成交量：186.97万

成交额：544.13万

市值：10.79亿

市盈率：-14.40

高：2.990

开：2.850

低：2.810

收：2.730

52周最高：5.870

52周最低：1.430

股本：3.72亿

流通股本：2.74亿

量比：0.64

换手率：0.68%

股息：- -

股息率：- -

每股收益(TTM):-0.201

每股收益(LYR):-0.201

净资产收益率：-54.37%

总资产收益率：-33.76%

市净率：11.96

市盈率(LYR):-14.40

数据加载中...

总览公司新闻资讯公告

概念

no data

没有相关数据

资金流向

资金流入：

资金流出：

新闻资讯

Clarity Pharmaceuticals表示靶向铜诊疗产品及临床开发项目不受美国100%关税影响

CLARITY PHARMACEUTICALS LTD确认美国临床试验的同位素及药品制造商均设在美国本土

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券 | 轻松买卖美股港股A股/美债/ETF/Crypto/期权期货","description":"老虎证券提供多项优惠： 港股&Crypto 0佣0平台费、A股通一年免佣、美股期权0佣、IPO打新0融资利息0手续费。 美股1美元起投，免费实时行情与多种工具，立即开户享更多优惠！","keywords":"老虎证券,老虎证券开户,老虎证券香港,老虎证券登录,老虎证券官网,香港证券开户,证券公司开户,股票开户,香港证券公司,香港证券,证券公司,股票投资,投资app,投资平台,股票买卖,股票交易平台,股票app,证券app,新手投资","social":{"ogDescription":"老虎证券提供多项优惠： 港股&Crypto 0佣0平台费、A股通一年免佣、美股期权0佣、IPO打新0融资利息0手续费。 美股1美元起投，免费实时行情与多种工具，立即开户享更多优惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/CU6.AU"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"CU6.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"CU6.AU\",,,,,undefined,":{"symbol":"CU6.AU","market":"AU","secType":"STK","nameCN":"CLARITY PHARMACEUTICALS LTD","latestPrice":2.9,"timestamp":1770613920000,"preClose":2.73,"halted":0,"volume":1869745,"delay":0,"changeRate":0.062271062271062244,"nameEN":"CLARITY PHARMACEUTICALS LTD","floatShares":274264090,"shares":372030071,"eps":-0.201427,"marketStatus":"未开盘","change":0.17,"latestTime":"02-09 16:12:00 AEDT","open":2.85,"high":2.99,"low":2.81,"amount":5441323,"amplitude":0.065934,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.201427,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":0,"beginTime":1770678000000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":2.73,"openAndCloseTimeList":[[1770591600000,1770613200000]],"volumeRatio":0.6406565521499517,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"CU6.AU\",,,,,undefined,":{"symbol":"CU6.AU","floatShares":274264090,"roa":"-33.76%","roe":"-54.37%","lyrEps":-0.201427,"volumeRatio":0.6406565521499517,"shares":372030071,"dividePrice":0,"high":2.99,"amplitude":0.065934,"preClose":2.73,"low":2.81,"week52Low":1.43,"pbRate":"11.96","psRate":"114.01","week52High":5.87,"institutionHeld":0,"latestPrice":2.9,"eps":-0.201427,"divideRate":0,"volume":1869745,"delay":0,"ttmEps":-0.201427,"open":2.85,"prevYearClose":3.38,"prevWeekClose":2.73,"prevMonthClose":3.07,"prevQuarterClose":3.38,"fiveDayClose":3.08,"twentyDayClose":3.8,"sixtyDayClose":4.62,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CU6.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CU6.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CU6.AU\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1142166450","title":"Clarity Pharmaceuticals表示靶向铜诊疗产品及临床开发项目不受美国100%关税影响","url":"https://stock-news.laohu8.com/highlight/detail?id=1142166450","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1142166450?lang=zh_cn&edition=fundamental","pubTime":"2025-09-26 11:11","pubTimestamp":1758856278,"startTime":"0","endTime":"0","summary":"Clarity Pharmaceuticals宣布，公司的靶向铜诊疗产品以及相关临床开发项目将不会受到美国实施的100%关税政策影响。\n该公司强调，尽管面临新的贸易政策挑战，其核心业务运营和产品开发计划仍将按既定方向推进，确保为患者提供创新的诊疗解决方案不会因外部贸易环境变化而受到干扰。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","CU6.AU"],"gpt_icon":0},{"id":"1176194720","title":"CLARITY PHARMACEUTICALS LTD确认美国临床试验的同位素及药品制造商均设在美国本土","url":"https://stock-news.laohu8.com/highlight/detail?id=1176194720","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1176194720?lang=zh_cn&edition=fundamental","pubTime":"2025-09-26 11:11","pubTimestamp":1758856277,"startTime":"0","endTime":"0","summary":"CLARITY PHARMACEUTICALS LTD日前宣布，该公司已确认为其美国临床试验站点提供服务的所有同位素和药物产品制造商均位于美国境内。\n这一确认表明，CLARITY PHARMACEUTICALS LTD在美国开展的临床试验项目将完全依托本土制造商的产能和服务，确保供应链的稳定性和合规性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CU6.AU","BK7096"],"gpt_icon":0}],"pageSize":4,"totalPage":1,"pageCount":1,"totalSize":2,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/CU6.AU\",params:#limit:6,delay:true,,,undefined,":[]}}